{"id":292,"date":"2026-11-19T02:03:26","date_gmt":"2026-11-19T02:03:26","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=292"},"modified":"2026-11-19T02:03:26","modified_gmt":"2026-11-19T02:03:26","slug":"c4x3256-rocavorexant-ox1r-process-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/c4x3256-rocavorexant-ox1r-process-dossier\/","title":{"rendered":"C4X3256 (Rocavorexant): First Scale-Up Campaign for a Selective Orexin-1 Receptor Antagonist \u2014 Process Intelligence Dossier"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">The problem: inherit a route, then make it manufacturable<\/h2>\n\n\n\n<p>When <strong>Indivior<\/strong> in-licensed the selective <strong>orexin-1 receptor (OX\u2081R) antagonist<\/strong> program <strong>C4X3256 (INDV2000, rocavorexant)<\/strong> from C4X Discovery, it inherited a route that had delivered two early batches (480 g, then a 4.2 kg cGMP lot) at excellent purity \u2014 but with a list of scale-up liabilities: a telescoped Stage 1\/2 of &#8220;complex equilibria,&#8221; a <strong>LiAlH\u2084<\/strong> amide reduction, an <strong>mCPBA<\/strong> oxidation, a <strong>highly toxic TMSCN<\/strong> step, a <strong>structural-alert pyridine N-oxide<\/strong> (ICH M7), a corrosive <strong>SOCl\u2082<\/strong> acid-chloride endgame, and high-molecular-weight salt intermediates that forced salt-break operations. This is the archetypal post-in-licensing problem: a chemistry that <em>works<\/em> is not yet a chemistry you can <em>run<\/em>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The strategy: a convergent 10-stage route, two halves joined by T3P<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"2407\" height=\"1478\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rocavorexant_scheme.png\" alt=\"\" class=\"wp-image-288\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rocavorexant_scheme.png 2407w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rocavorexant_scheme-300x184.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rocavorexant_scheme-1024x629.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rocavorexant_scheme-768x472.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rocavorexant_scheme-1536x943.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rocavorexant_scheme-2048x1258.png 2048w\" sizes=\"auto, (max-width: 2407px) 100vw, 2407px\" \/><figcaption class=\"wp-element-caption\">Convergent 10-stage route to C4X3256 (rocavorexant): amine 6 + acid 10 united by a T3P coupling. Redrawn by Astinova Bio Labs (RDKit); no paper figures reused.<\/figcaption><\/figure>\n\n\n\n<p>The campaign kept the molecule&#8217;s convergent logic and rebuilt the operations around it. <strong>Two advanced intermediates<\/strong> are made in parallel and united in the final stage:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n\n<li><strong>Amine 6<\/strong> \u2014 five stages from <strong>L-alaninamide\u00b7HCl<\/strong>: reductive amination (PhCHO), N-methylation, <strong>amide\u2192amine reduction<\/strong>, S_NAr onto <strong>2-chloro-5-(trifluoromethyl)pyrazine<\/strong>, then debenzylation.<\/li>\n\n\n<li><strong>Acid 10<\/strong> \u2014 four stages from <strong>5-bromo-2-methylpyridine<\/strong>: <strong>Cu-catalyzed Ullmann N-arylation<\/strong> with 1,2,3-triazole (N2-regioselective), N-oxidation, a <strong>Reissert-type cyanation<\/strong> (TMSCN\/BzCl) installing the C-2 nitrile, and hydrolysis.<\/li>\n\n\n<li><strong>Final coupling<\/strong> \u2014 the two fragments joined with <strong>T3P \/ iPr\u2082NEt in EtOAc<\/strong> to give <strong>C4X3256 monohydrate<\/strong> in 80%.<\/li>\n\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">The process intelligence: what actually changed<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th>Liability in the inherited route<\/th><th>Scale-up fix<\/th><\/tr><\/thead><tbody><tr><td>Stage 1\/2 telescope = &#8220;complex equilibria,&#8221; low\/variable yield<\/td><td><strong>Isolate crystalline amine 2<\/strong> as a control point; revised Stage 1 (PhCHO\/NaOH\/Pd-C, MeOH) completes in 1\u20132 h<\/td><\/tr><tr><td>Poorly crystallizing amide intermediate 3<\/td><td><strong>Telescope Stages 2\u21923 in THF<\/strong>, avoiding its isolation<\/td><\/tr><tr><td>High-MW trimesic-acid salt of 6 forcing a salt break<\/td><td><strong>Improved 6 and 10<\/strong> so the final amide forms <strong>without a preliminary salt break<\/strong><\/td><\/tr><tr><td>mCPBA N-oxidation<\/td><td><strong>Peracetic acid<\/strong><\/td><\/tr><tr><td>SOCl\u2082 acid-chloride endgame (corrosive, water-sensitive)<\/td><td><strong>T3P coupling<\/strong> \u2014 equimolar acid 10 \/ amine 6, EtOAc, 35\u201345 \u00b0C<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The toxic steps that remain are handled, not hidden: the <strong>TMSCN\/BzCl<\/strong> cyanation (HCN risk) runs cold with controlled addition, and all <strong>cyanide-containing waste is quenched, basified, and consigned<\/strong> for licensed disposal. The resulting <strong>N-oxide (ICH M7 alert)<\/strong> is carried as a transient, purged downstream.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The outcome<\/h2>\n\n\n\n<p>Two GMP batches delivered <strong>14.4 kg (77%) and 14.8 kg (80%)<\/strong> \u2014 <strong>29.2 kg total<\/strong>, ~78% average for the final stage \u2014 of <strong>C4X3256 monohydrate (Form 1)<\/strong> as white acicular needles, <strong>99.7\u201399.8% HPLC<\/strong> and <strong>100% ee<\/strong>. KF (3.8\u20134.0% w\/w H\u2082O) confirmed the monohydrate (theory 4.1%); drying was capped at 50 \u00b0C to protect the hydrate. Tightening the crystallization concentration pulled D90 from 311 \u00b5m (prior lot) to <strong>52 \u00b5m<\/strong> \u2014 a formulation-ready particle size out of the final step.<\/p>\n\n\n\n<p>The drug substance itself: <strong>N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoromethyl)pyrazin-2-yl]amino}propan-2-yl]pyridine-2-carboxamide<\/strong> (anhydrous C\u2081\u2088H\u2081\u2089F\u2083N\u2088O, MW 420.4), isolated as the 1:1 hydrate.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why it matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n\n<li><strong>A textbook de-risking.<\/strong> New crystalline control points, two telescopes, and reagent swaps (peracetic acid for mCPBA, <strong>T3P for SOCl\u2082<\/strong>) turned an inherited medicinal-chemistry route into a kilogram-scale GMP process.<\/li>\n\n\n<li><strong>Convergence pays.<\/strong> Building amine 6 and acid 10 separately and coupling last keeps the longest linear sequence short and the high-value fragments protected.<\/li>\n\n\n<li><strong>Particle engineering at the API step.<\/strong> Hitting Form 1 monohydrate with a 52 \u00b5m D90 straight from crystallization is the kind of endgame control that formulation teams actually ask for.<\/li>\n\n<\/ul>\n\n\n\n<p><strong>Reference:<\/strong> Breen, G. F.; Carey, J. S.; Claveau, R.; Maczka, M. &#8220;Synthesis of a Selective Orexin 1 Receptor Antagonist: First Scale-Up Campaign Following In-Licensing.&#8221; <em>Org. Process Res. Dev.<\/em> <strong>2026<\/strong>, DOI: 10.1021\/acs.oprd.6c00444. (Work by Indivior and Almac Sciences; NIDA award UG3DA050308.)<\/p>\n\n\n\n<p><em>Source article is CC-BY-NC-ND \u2014 no paper figures are reused here. Both visuals are original to Astinova Bio Labs: the convergent route and all structures redrawn with RDKit\/Matplotlib.<\/em><\/p>\n\n\n\n<p><em>Astinova Bio Labs develops and de-risks synthetic routes like this one \u2014 convergent design, reagent and safety swaps, telescoping, and crystallization\/particle control. <a href=\"https:\/\/astinovabiolabs.com\/\">Talk to us<\/a> about your process.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>De-risking an in-licensed route: Indivior and Almac&#8217;s convergent 10-stage, 29.2 kg scale-up of the selective orexin-1 antagonist C4X3256 (rocavorexant), with T3P replacing the acid-chloride endgame.<\/p>\n","protected":false},"author":1,"featured_media":287,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[110,111,115,109,114,112,113],"class_list":["post-292","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-process-chemistry","tag-orexin-1-receptor","tag-ox1r-antagonist","tag-reductive-amination","tag-rocavorexant","tag-scale-up","tag-t3p-coupling","tag-ullmann-reaction"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=292"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/292\/revisions"}],"predecessor-version":[{"id":295,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/292\/revisions\/295"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/287"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}